Pflügers Archiv - European Journal of Physiology

, Volume 461, Issue 3, pp 317–324

Angiotensin inhibition and longevity: a question of hydration

Invited Review

DOI: 10.1007/s00424-010-0911-4

Cite this article as:
Thornton, S.N. Pflugers Arch - Eur J Physiol (2011) 461: 317. doi:10.1007/s00424-010-0911-4


With the advancement of medical and investigative science, it is somewhat surprising that although it is possible to stabilise medical patients with hypertension and the associated kidney dysfunction, obesity, diabetes and even cancer, there is still no clear method of significantly reducing these chronic disease pathologies, and thus, extending life expectancy. There is one hormone common to these pathologies, the antagonism of which goes some way to clinical improvements, and this is angiotensin, which is released during hypovolaemia. Angiotensin antagonists are used to treat many of these pathologies, and it has been shown in the obesity literature that angiotensin antagonists decrease weight, but also increase the drinking of water. Increased cellular hydration, and hence, improved mitochondrial metabolism could be one of the mechanisms for the reduction in weight seen in these studies, as well as for reducing the other pathologies, all showing metabolic dysfunction. It appears that the application of straightforward physiological regulation might be an appropriate medical approach to the prevention of hypertension, kidney disease, obesity, diabetes and cancer, and thus, to an increased life expectancy.


Angiotensin Hydration Longevity 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Université Henri PoincaréNancy UniversitéNancyFrance
  2. 2.INSERM, U961Vandoeuvre les NancyFrance
  3. 3.U961 UHP-INSERMRisque cardiovasculaire, rigidité-fibrose et hypercoagulabilité, Faculté de MédecineVandoeuvre Les NancyFrance

Personalised recommendations